Use of evidence-based pharmacotherapy after myocardial infarction in Estonia
- Cost-effectiveness of simvastatin in the secondary prevention of coronary artery disease in Canada. Riviere, Marc; Wang, Shanshan // CMAJ: Canadian Medical Association Journal;04/01/97, Vol. 156 Issue 7, p991
Determines the cost-effectiveness of simvastatin in the secondary prevention of coronary artery disease (CAD) in Canada. Outcome measures of the study; Reduced mortality and morbidity among patients given simvastatin compared to control subjects; Suggestion that simvastatin provides a...
- Many CAD patients referred for invasive intervention are on suboptimal medical therapy. // Modern Medicine;May96, Vol. 64 Issue 5, p30
Reports on the suboptimal chemotherapy of patients with coronary artery disease (CAD). Safety of using suboptimal medical therapy instead of invasive interventions.
- Increased drug therapy may be all that CAD patients need. // Geriatrics;May96, Vol. 51 Issue 5, p56
Reports on treatment of people with coronary artery disease. Effectiveness of increased medications.
- Fix for furry arteries. Coghlan, Andy // New Scientist;11/15/97, Vol. 156 Issue 2108, p6
Highlights research on drugs for tackling the root cause of blockages in coronary arteries. Suppression of levels of cholesterol; Disruption of endothelial inflammation; Prevention of activation of genes in endothelial cells that amplify inflammation.
- Heart disease in women: Special symptoms, special risks. // Consumer Reports on Health;May97, Vol. 9 Issue 5, p54
Investigates coronary heart disease in women. Prevalence of risk factors for coronary heart disease in women; Differences in the risk factors of heart disease in men and women; Importance of exercise and a low-fat diet on reducing the risk of heart disease. INSET: Diagnosis in women: Why the...
- Combo therapy for 2Â° CHD prevention not uniform in the US. // PharmacoEconomics & Outcomes News;2/20/2010, Issue 597, p6
The article discusses research by J. Tija et al published in the January 2010 issue of the journal of "Drugs and Aging" on the effectivity of combination drug therapy for the secondary prevention of coronary heart disease (CHD) in the U.S. and the subpopulation in danger of underusing the therapy.
- Lipid-lowering therapy after coronary artery bypass grafting: Time for more aggressive intervention. Lucas Jr., B. Daniel // American Journal of Health-System Pharmacy;11/1/2002, Vol. 59 Issue 21, p2101
Reflects the approach of health care providers toward lipid management in the patient with coronary heart disease (CHD). Comparison between primary and secondary prevention of CHD; Evaluation of the lipid-lowering therapy ; Attempts to enhance medical compliance and reduce cholesterol levels.
- AFFAIRS OF THE HEART. Karpa, Kelly Dowhower // Drug Topics;10/20/2003, Vol. 147 Issue 20, pHSE11
Proposes the use of cocktail drugs to treat acute coronary syndrome. Role of pharmacists; Function of beta-blockers; Function of antiplatelet/anticoagulation drugs; Lipid-lowering medications.
- A CASE REPORT OF 5-FLUOROURACIL-INDUCED CORONARY ARTERY VASOSPASM. Connolly, Suzanne; Scott, Peter; Cochrane, L. David; Harte, Robert // Ulster Medical Journal;2010, Vol. 79 Issue 3, p135
A letter to the editor is presented that describes the case of a 76-year-old man diagnosed with coronary artery vasopasm induced by the chemotherapeutic agent 5-Flurouracil.